Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N, WKN: A422EZ) has entered into a definitive share purchase agreement to acquire Vancouver-based Quantum.IQ Technologies Inc., a move that expands its technology platform into quantum-resistant cybersecurity, cryptographic intelligence and enterprise security infrastructure modernization. The acquisition is expected to broaden Redwood’s exposure beyond artificial intelligence and operational intelligence into post-quantum cybersecurity, enterprise resilience and critical infrastructure modernization, subject to customary closing conditions and regulatory approvals.
Under the agreement, Redwood will issue up to 14,033,558 common shares valued at approximately $2.98 per share, including 7,033,558 base shares and up to 7 million milestone shares tied to customer, revenue and EBITDA targets. The company stated that the combination of its AI capabilities with Quantum.IQ’s post-quantum cryptography platform is expected to strengthen its position in security-sensitive markets serving government, defense, financial services and critical infrastructure organizations.
This acquisition is significant as it positions Redwood at the intersection of artificial intelligence and quantum-resistant cybersecurity, two rapidly evolving fields. With the increasing threat of quantum computers breaking current encryption standards, organizations are seeking solutions that can safeguard sensitive data against future quantum attacks. By integrating Quantum.IQ’s cryptographic intelligence, Redwood aims to offer a comprehensive suite for enterprise security modernization.
For more details, the full press release can be accessed at https://ibn.fm/brYSH.
Redwood AI Corp. uses advanced artificial intelligence to accelerate chemistry R&D, with the aim of assisting in drug discovery and development, and furthering defense and safety solutions. The company combines expertise in chemistry, AI, and manufacturing to streamline drug synthesis and scale-up. Its platform is designed to enable faster, more efficient development of new therapies and chemistry-driven applications.
The latest news and updates relating to RDWCF are available in the company’s newsroom at https://ibn.fm/RDWCF.
